Rodent pain models play an important role in understanding the mechanisms of nociception and have accelerated the search for new treatment approaches for pain. Creating an objective metric for orofacial nociception in these models presents significant technical obstacles. No animal assay accurately measures pain-induced orofacial dysfunction that is directly comparable to human orofacial dysfunction. We developed and validated a high throughput, objective, operant, nociceptive animal assay, and an instrument to perform the assay termed the dolognawmeter, for evaluation of conditions known to elicit orofacial pain in humans. Using the device our assay quantifies gnawing function in the mouse. We quantified a behavioral index of nociception and demonstrated blockade of nociception in three models of orofacial pain: (1) TMJ inflammation, (2) masticatory myositis, and (3) head and neck cancer. This assay will be useful in the study of nociceptive mediators involved in the development and progression of orofacial pain conditions and it will also provide a unique tool for development and assessment of new therapeutic approaches.
Cancer pain creates a poor quality of life for cancer patients. Chronic
cancer pain is a major public health problem in which little progress has been made in treatment. In this dissertation we propose that pain is the result of imbalance between algesic and analgesic mediators within the cancer microenvironment. Furthermore, this imbalance arises from downregulation by hypermethylation of genes coding for analgesic mediators, and re-expression of these mediators by demethylating drugs produces analgesia. We determine whether EDNRB and OPRM1, genes of receptors mediating analgesia, are hypermethylated in the tumors of oral cancer patients, compared to normal and oral dysplasia controls. To determine whether the expression of these genes mediates analgesia, we create an orthotopic oral cancer mouse model, where we re-express the EDNRB or OPRM1 gene using adenoviruses. Re-expression of EDNRB results in mechanical analgesia, and re-expression of OPRM1 results in mechanical and thermal analgesia in the mouse cancer pain model. Finally, we determine the analgesic potential of demethylating drugs decitabine and zebularine in the mouse cancer model. We show that combination therapy with these two drugs results in an antiproliferative and analgesic effect in the mouse model.
Cancer pain is a frequent and disabling consequence for many patients yet the mechanism of cancer pain remains unknown largely due to its complex etiology. The objective of this thesis work was to investigate the potential of a peptide produced by carcinoma cells, endothelin, as a novel target for cancer pain management. This study provided evidence in support of Hypothesis 1: Oral squamous carcinoma cells produce endogenous opioids in response to changes in endothelin-1 signaling. Effects of endothelin-1 (ET-1) signaling on secretion of opioids by oral squamous cell carcinoma (SCC) were studied in vitro. Oral SCC cell line HSC-3 produces abundant ET-1 that can act in both an autocrine or paracrine manner. In the untreated oral SCC cells, endogenous opioids were detected in both cultured media and cell lysates. When treated with Endothelin-A receptor antagonist, secreted levels of &beta-endorphin and leu-enkephalin were increased; whereas treatment with Endothelin-B receptor agonist increased production of only &beta-endorphin. This apparent regulation of endogenous opioid levels by endothelin receptor drugs in vitro procured evidence suggesting that Hypothesis 2: Endothelin-A receptor antagonist and Endothelin-B receptor agonist attenuate carcinoma-induced nociception in cancer animals through regulation of endogenous opioids. Endothelin-A (ET-AR) antagonism has been demonstrated previously to attenuate carcinoma-mediated hyperalgesia in an orthotopic cancer pain mouse model. In this study, effects of ET-BR agonist in vivo were evaluated and determined to also result in significant increase in paw withdrawal thresholds, indicating attenuation of cancer-induced nociception. When peripheral &mu- or &delta-opioid receptor antagonists were administered following ET-AR antagonism, nociceptive attenuation was completely reversed. Attenuation from ET-BR agonism was likewise reversed upon administration of &mu-opioid receptor antagonist. Combined results demonstrate that endogenous opioids are the likely mediators responsible for attenuation of carcinoma-induced nociception with either ET-AR antagonist or ET-BR agonist.
These novel findings suggest that there exist innate modulation of pain by SCCs involving endogenous opioids that can be exploited through manipulation of endothelin activity in the cancer micro-environment. Regulation of ET-AR or ET-BR signaling may be targets for future innovations for cancer pain management.
To use type Ia supernovae as standard candles for cosmology we need accurate broadband magnitudes. In practice the observed magnitude may differ from the ideal magnitude-redshift relationship either through intrinsic inhomogeneities in the type Ia supernova population or through observational error. Here we investigate how we can choose filter bandpasses to reduce the error caused by both these effects. We find that bandpasses with large integral fluxes and sloping wings are best able to minimise several sources of observational error, and are also least sensitive to intrinsic differences in type Ia supernovae. The most important feature of a complete filter set for type Ia supernova cosmology is that each bandpass be a redshifted copy of the first. We design practical sets of redshifted bandpasses that are matched to typical high resistivity CCD and HgCdTe infra-red detector sensitivities. These are designed to minimise systematic error in well observed supernovae, final designs for specific missions should also consider signal-to-noise requirements and observing strategy. In addition we calculate how accurately filters need to be calibrated in order to achieve the required photometric accuracy of future supernova cosmology experiments such as the SuperNova-Acceleration-Probe (SNAP), which is one possible realisation of the Joint Dark-Energy mission (JDEM). We consider the effect of possible periodic miscalibrations that may arise from the construction of an interference filter.
Cookie SettingseScholarship uses cookies to ensure you have the best experience on our website. You can manage which cookies you want us to use.Our Privacy Statement includes more details on the cookies we use and how we protect your privacy.